Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

Breast Cancer Research

Volumn 14, Issue 4, 2012, Pages

  Byrski, Tomasz ^a   Dent, Rebecca ^b   Blecharz, Pawel ^c   Foszczynska Kloda, Malgorzata ^d   Gronwald, Jacek ^a   Huzarski, Tomasz ^a   Cybulski, Cezary ^a   Marczyk, Elzbieta ^c   Chrzan, Robert ^e   Eisen, Andrea ^b   Lubinski, Jan ^a   Narod, Steven A ^b  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d Regional Oncology Hospital   (Poland)

^e JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BRCA1 PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; ONDANSETRON; PABI DEXAMETHASON; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; BREAST NEOPLASMS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CISPLATIN; FEMALE; GENES, BRCA1; HETEROZYGOTE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84866165483     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3231     Document Type: Article

References (24)

1. Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD. A significant response to neo-adjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002, 39:608-610. 10.1136/jmg.39.8.608, 1735193, 12161606.
2. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wiśniowski R, Siolek M, Narod SA, Lubinski J. Response to neoadjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008, 108:289-296. 10.1007/s10549-007-9600-1, 17492376.
3. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134. 10.1056/NEJMoa0900212, 19553641.
4. Marcus JN, Watson P, Page DL, Narod SA, Tonin P, Lenoir GM, Serova O, Lynch HT. BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat 1997, 44:275-277. 10.1023/A:1005830230664, 9266108.
5. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storger-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Bignon YJ, Struewing JP, Spurr NK, Bishop DT, Klijn JG, Devilee P, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998, 90:1138-1145. 10.1093/jnci/90.15.1138, 9701363.
6. Johannsson OT, Idvall I, Anderson C, Bord A, Barkardottir RB, Egilsson V, Olsson H. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997, 33:362-371. 10.1016/S0959-8049(97)89007-7, 9155518.
7. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003, 95:1482-1485. 10.1093/jnci/djg050, 14519755.
8. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004, 96:1659-1668. 10.1093/jnci/djh312, 15547178.
9. Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 2005, 5:388-393. 10.1016/j.coph.2005.03.006, 15955736.
10. Górski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Pluzanski A, Bebenek M, Fischer-Maliszewska L, Grzybowska E, Narod SA, Lubinski J. Founder mutations in BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet 2000, 66:1963-1968. 10.1086/302922, 1378051, 10788334.
11. Górski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawaicka M, Bebenek M, Sorokin D, Fiszer-Maliszewska L, Haus O, Janiszewska H, Niepsuj S, Gozdz S, Zaremba L, Posmyk M, Pluzanska M, Kilar E, Czudowska D, Wasko B, Miturski R, Kowalczyk JR, Urbanski K, Szwiec M, Koc J, Debniak B, Rozmiarek A, Debniak T, Cybulski C, et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004, 110:683-686. 10.1002/ijc.20162, 15146557.
12. Lubinski J, Gorski B, Huzarski T, Byrski T, Gronwald J, Serrano-Fernandez P, Domagala W, Chosia M, Ucinski M, Grzybowska E, Lange D, Maka B, Mackiewicz A, Karczewska A, Breborowicz J, Lamperska K, Stawicka M, Gozdecka-Grodecka S, Bebenek M, Sorokin D, Wojnar A, Haus O, Sir J, Mierzwa T, Niepsuj S, Gugala K, Gozdz S, Sygut J, Kozak-Klonowska B, Musiatowicz B, et al. BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat 2006, 99:71-76. 10.1007/s10549-006-9182-3, 16541315.
13. Byrski T, Huzarski T, Dent R, Gronwald J, Cybulski C, Lubinski J, Narod SA. Response to neoadjuvant therapy with Cisplatin in BRCA1-Positive breast cancer patients. Breast Cancer Res Treat 2009, 115:359-363. 10.1007/s10549-008-0128-9, 18649131.
14. Therasse P, Arbuck SG, Eisenhauser EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
15. Kelland L. The resurgence of platinum based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584. 10.1038/nrc2167, 17625587.
16. Sledge GW, Loehrer PJ, Roth BJ, Einhorn LH. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 1988, 6:1811-1818.
17. Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB, Bartels CC, Tilanus-Linthorst MM, Blom J, Huijskens E, Jager A, van den Ouweland A, van Geel B, Hoonng MJ, Brekelmans CT, Klijn JG. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009, 27:3764-3771. 10.1200/JCO.2008.19.9067, 19564533.
18. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244. 10.1016/S0140-6736(10)60892-6, 20609467.
19. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Dent R, Lubinski J, Narod S. Pathological complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010, 28:375-379. 10.1200/JCO.2008.20.7019, 20008645.
20. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME. BRCAness syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008, 26:5530-5536. 10.1200/JCO.2008.16.1703, 18955455.
21. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003, 97:2187-2195. 10.1002/cncr.11310, 12712470.
22. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008, 68:2581-2586. 10.1158/0008-5472.CAN-08-0088, 2674369, 18413725.
23. Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, Klijn C, van der Heijden I, van der Gulden H, Wientjens E, Pieterse M, Catteau A, Green P, Solomon E, Morris JR, Jonkers J. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 2011, 20:797-809. 10.1016/j.ccr.2011.11.014, 22172724.
24. Ghadirian P, Robidoux A, Zhang P, Royer R, Akbari M, Zhang S, Fafard E, Costa M, Martin G, Potvin C, Patocskai E, Larouche N, Younan R, Nassif E, Giroux S, Narod SA, Rousseau F, Foulkes WD. The contribution of founder mutations to early-onset breast cancer in French-Canadian women. J Clin Genet Clin Genet 2009, 76:421-426.